Detalles de la búsqueda
1.
Patterns of progression in patients treated for immuno-oncology antibodies combination.
Cancer Immunol Immunother
; 70(1): 221-232, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700090
2.
Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
Br J Cancer
; 119(8): 937-939, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30327567
3.
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.
Invest New Drugs
; 32(2): 312-22, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23979492
4.
Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting.
Chin J Cancer
; 33(12): 620-4, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25418191
5.
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Invest New Drugs
; 31(3): 623-30, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22688291
6.
An international multicentric phase â ¢ randomized controlled trial of time-acupoints-space acupuncture for the prevention of chemotherapy-induced fatigue in patients with early stage breast cancer: a study protocol.
J Tradit Chin Med
; 42(2): 289-295, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35473351
7.
Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.
Eur J Cancer
; 167: 42-53, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35378410
8.
A catalyst for change: the European cancer Patient's Bill of Rights.
Oncologist
; 19(3): 217-24, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24493667
9.
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
Cancer Res
; 67(13): 6253-62, 2007 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17616683
10.
Intestinal bacterial ß-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity.
Pharmacol Ther
; 199: 1-15, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30831128
11.
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.
Nat Clin Pract Oncol
; 5(5): 268-78, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18349858
12.
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Clin Cancer Res
; 13(6): 1801-9, 2007 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17363536
13.
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.
Eur J Cancer
; 101: 160-164, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30071444
14.
Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.
Eur J Cancer
; 98: 17-22, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29859337
15.
Therapeutics discovery: From bench to first in-human trials.
Biomed Rep
; 8(3): 275-282, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29564125
16.
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.
Oncotarget
; 9(11): 9741-9750, 2018 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29515767
17.
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
Eur J Cancer
; 92: 1-10, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29413684
18.
Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicine.
Future Oncol
; 8(10): 1215-8, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23130922
19.
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Eur J Cancer
; 84: 212-218, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28826074
20.
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.
J Clin Oncol
; 23(31): 7871-80, 2005 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16172454